Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Secukinumab to Decrease Risk of Immune Related Adverse Events in Metastatic Melanoma
NCT07237594Phase 1Recruiting
- Sponsor
- Duke University
- Start
- Mar 2026
- Primary completion
- Jun 2027
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of secukinumab in immune-related adverse events (irAEs), sponsored by Duke University. Primary endpoints: Safety of administering secukinumab up to 3 years and Feasibility of administering secukinumab up to 3 years. Started Mar 2026; status: recruiting.
02
Drugs
secukinumab
03
Conditions
immune-related adverse events (irAEs)
Beyond the preview
Go deeper on NCT07237594.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07237594.